Cost-Effectiveness of Pre-emptive DPYD Genotyping Compared to Standard of Care Among Patients Receiving Fluoropyrimidine-Based Anti-cancer Treatment in Australia. [PDF]
Glewis S +12 more
europepmc +1 more source
Association between miRNA expression profiles and polymorphisms of dihydropyrimidine dehydrogenase drug-metabolizing gene in patients with colorectal cancer receiving 5-fluorouracil. [PDF]
Phannasil P +8 more
europepmc +1 more source
Uptake of DPYD and UGT1A1 testing in Italy and adherence to pharmacogenetic guidelines: A 5-year perspective from an EQA provider. [PDF]
Roncato R +8 more
europepmc +1 more source
Effectiveness of pharmacogenomics-guided dosing in improving treatment outcomes. [PDF]
Karthikeyan LV +5 more
europepmc +1 more source
Suspected capecitabine-induced fatal toxicity in the context of a new DPYD variant. [PDF]
Thet PN +3 more
europepmc +1 more source
Transcriptomics-based identification of lysine crotonylation-related biomarkers in pre-eclampsia. [PDF]
Li J, Li X, Chen X, Guo Y, Yang F.
europepmc +1 more source
Author Correction: P53 represses pyrimidine catabolic gene dihydropyrimidine dehydrogenase (DPYD) expression in response to thymidylate synthase (TS) targeting. [PDF]
Gokare P +5 more
europepmc +1 more source
Towards Personalized Chemotherapy in Gastrointestinal Cancers: Prospective Analysis of Pharmacogenetic Variants in a Russian Cohort. [PDF]
Fedorinov D +9 more
europepmc +1 more source
Polygenic risk scores in pharmacogenomics: methodological challenges, current applications, and perspectives for clinical implementation. [PDF]
Mathey CM +3 more
europepmc +1 more source

